Winton Group’s Avalo Therapeutics AVTX Stock Holding History

Winton Group’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-4	Closed	-$60K	–	1401
2019 Q4	$60K	Sell	4 -6	-60%	-$63.3K	﹤0.01%	1503
2019 Q3	$97K	Buy	+10	New	+$112K	﹤0.01%	1466

Other funds holding AVTX

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Winton Group's AVTX Position: Q1 2020 in Review

Winton Group sold out of Avalo Therapeutics (AVTX) in Q1 2020, closing a stake of 4 shares — an estimated $60K sold.

Winton Group first reported a position in AVTX in Q3 2019 and held it in 2 quarters. The position peaked at $97K in Q3 2019. 43 funds tracked by Wall St. Rank hold AVTX as of Q1 2020.

Winton Group reported no remaining Avalo Therapeutics position as of Q1 2020 after selling out during the quarter.
Winton Group sold 4 Avalo Therapeutics shares in Q1 2020, an estimated $60K.
Winton Group first reported a position in Avalo Therapeutics in Q3 2019 and held it in 2 quarters.
Winton Group's Avalo Therapeutics position peaked at $97K in Q3 2019.
43 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2020.

Based on Winton Group's 13F filing for Q1 2020, filed 11 May 2020.